Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001046020 | SCV001209901 | uncertain significance | Charcot-Marie-Tooth disease type 2 | 2022-05-21 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The proline amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 843403). This variant has not been reported in the literature in individuals affected with KIF1B-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 1626 of the KIF1B protein (p.Ala1626Pro). |
Ambry Genetics | RCV004031421 | SCV002635602 | uncertain significance | not specified | 2023-08-28 | criteria provided, single submitter | clinical testing | The p.A1626P variant (also known as c.4876G>C), located in coding exon 43 of the KIF1B gene, results from a G to C substitution at nucleotide position 4876. The alanine at codon 1626 is replaced by proline, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Ce |
RCV003425891 | SCV004128369 | uncertain significance | not provided | 2023-06-01 | criteria provided, single submitter | clinical testing | KIF1B: PM2, BP4 |